{"entity":{"id":"adcytherix","kind":"company","name":"Adcytherix","aka":[],"tldr":"Adcytherix is a French company developing antibody-drug conjugates with new kinds of cell-killing drug, aimed at cancers that have stopped responding to existing conjugates. Its first medicine was being prepared for human trials in late 2025.","summary":"Adcytherix, based in Marseille, develops antibody-drug conjugates built around novel payloads, intended for patients whose cancers are resistant to the current classes of ADC. Its lead candidate, ADCX-020, was being readied for clinical trial applications when the company announced a EUR 105 million (USD 122 million) Series A on 16 October 2025, led by Bpifrance and co-led by Kurma Partners, Andera Partners and Angelini Ventures, with Surveyor Capital and aMoon joining existing shareholders Pontifax, DawnBiopharma, Pureos Bioventures and RA Capital. The target of ADCX-020 and the cancers it will be tested in had not been disclosed.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.adcytherix.com/"},{"label":"EUR 105 million Series A release, October 2025","url":"https://www.biospace.com/press-releases/adcytherix-raises-eur-105m-series-a-to-accelerate-breakthrough-antibody-drug-conjugate-pipeline-with-strategic-focus-on-novel-payloads"}],"tags":[],"related":[],"cancers":[],"sections":["adcs"],"technologies":["adc"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not stated. The October 2025 release quotes the chief executive on work done 'since inception just 18 months ago', which would place founding around spring 2024, but no page states the year. The company website rendered only a one-line description when read, so pipeline details come from the release."],"hq":"Marseille","country":"FR","companyType":"biotech","website":"https://www.adcytherix.com/","stage":"startup","investors":["bpifrance","andera-partners","ra-capital"],"funding":[{"round":"Series A","year":2025,"amountUsd":122000000,"source":"https://www.biospace.com/press-releases/adcytherix-raises-eur-105m-series-a-to-accelerate-breakthrough-antibody-drug-conjugate-pipeline-with-strategic-focus-on-novel-payloads","note":"EUR 105 million; the release states the USD 122 million equivalent"}]},"route":"/companies/adcytherix/","neighbours":{"section":[{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"company":[{"id":"andera-partners","kind":"company","name":"Andera Partners","route":"/companies/andera-partners/"},{"id":"bpifrance","kind":"company","name":"Bpifrance","route":"/companies/bpifrance/"},{"id":"ra-capital","kind":"company","name":"RA Capital Management","route":"/companies/ra-capital/"}]}}